Calithera Biosciences, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Revenue:
Total revenue
Operating expenses:
Research and development
Research and development related to asset acquisition
General and administrative
Total operating expenses
Loss from operations
Interest income, net
Other income (expense):
Transaction costs allocable to warrant liabilities
Change in fair value of warrant liabilities
Interest and other income, net
Other income (expense), net
Net loss
Net loss per share, basic and diluted
Weighted average common shares used to compute net loss per share, basic and diluted
Deemed contribution from Series A preferred stock extinguishment
Net loss attributable to common stockholders - basic
Net loss per share attributable to common stockholders - basic
Net loss per share attributable to common stockholders - diluted
Weighted average common shares used to compute net loss per share attributable to common stockholders - basic
Weighted average common shares used to compute net loss per share attributable to common stockholders - diluted

Comments